意大利医学与介入放射学会关于疑似或COVID-19阳性患者中使用CT和人工智能的声明
意大利医学与介入放射学会(SIRM)就COVID-19疫情中影像检查选择与人工智能应用发布声明:推荐胸部X线作为一线影像工具、CT作为显示COVID肺炎典型特征的附加工具、肺部超声作为监测工具,并强调扫描设备消毒;SIRM支持人工智能作为预测与预后决策支持系统的研究,但不支持用CT联合人工智能进行筛查或作为诊断COVID-19的一线检查,且CT联合人工智能不能替代鼻咽拭子rRT-PCR分子诊断。
要点
- SIRM推荐胸部X线作为一线影像工具,CT作为显示COVID肺炎典型特征的附加工具。
- SIRM推荐肺部超声作为监测工具,并高度重视在发现任何疑似或阳性患者后对扫描设备执行适当消毒程序。
- SIRM不支持使用CT联合人工智能进行筛查或作为诊断COVID-19的一线检查,且其不能替代鼻咽拭子rRT-PCR。
核心结论
- SIRM推荐胸部X线作为一线影像工具,CT作为附加工具显示COVID肺炎典型特征,肺部超声作为监测工具。
- SIRM将确保在发现任何疑似或阳性COVID-19患者后对扫描设备执行适当消毒程序列为高优先级。
- SIRM支持人工智能作为预测和预后决策支持系统的研究,尤其在住院和重症监护患者中,并欢迎单中心或多中心研究进行临床验证。
- SIRM不支持使用CT联合人工智能进行筛查或作为诊断COVID-19的一线检查。
- SIRM指出CT联合人工智能不能替代鼻咽拭子rRT-PCR分子诊断试验用于疑似COVID-19患者。
研究设计与样本
- 本文为意大利医学与介入放射学会(SIRM)发布的声明。
- 声明基于COVID-19大流行在意大利自2020年2月开始并呈指数增长、病例数超过中国的背景。
诊断标准与关键数值
- SIRM推荐胸部X线作为一线影像工具。
- SIRM推荐CT作为附加工具,可显示COVID肺炎的典型特征。
- SIRM推荐肺部超声作为监测工具。
- SIRM不支持使用CT联合人工智能进行筛查或作为诊断COVID-19的一线检查。
- CT联合人工智能不能替代鼻咽拭子rRT-PCR分子诊断试验用于疑似COVID-19患者。
临床应用与阅片要点
- SIRM推荐将胸部X线作为一线影像工具,CT作为显示COVID肺炎典型特征的附加工具,肺部超声作为监测工具。
- SIRM将确保在发现任何疑似或阳性COVID-19患者后对扫描设备执行适当消毒程序列为高优先级。
- SIRM不支持使用CT联合人工智能进行筛查或作为诊断COVID-19的一线检查,且其不能替代鼻咽拭子rRT-PCR。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The COVID-19 pandemic started in Italy in February 2020 with an exponential growth that has exceeded the number of cases reported in China. Italian radiology departments found themselves at the forefront in the management of suspected and positive COVID cases, both in diagnosis, in estimating the severity of the disease and in follow-up. In this context SIRM recommends chest X-ray as first-line imaging tool, CT as additional tool that shows typical features of COVID pneumonia, and ultrasound of the lungs as monitoring tool. SIRM recommends, as high priority, to ensure appropriate sanitation procedures on the scan equipment after detecting any suspected or positive COVID-19 patients. In this emergency situation, several expectations have been raised by the scientific community about the role that artificial intelligence can have in improving the diagnosis and treatment of coronavirus infection, and SIRM wishes to deliver clear statements to the radiological community, on the usefulness of artificial intelligence as a radiological decision support system in COVID-19 positive patients. (1) SIRM supports the research on the use of artificial intelligence as a predictive and prognostic decision support system, especially in hospitalized patients and those admitted to intensive care, and welcomes single center of multicenter studies for a clinical validation of the test. (2) SIRM does not support the use of CT with artificial intelligence for screening or as first-line test to diagnose COVID-19. (3) Chest CT with artificial intelligence cannot replace molecular diagnosis tests with nose-pharyngeal swab (rRT-PCR) in suspected for COVID-19 patients.
引用
- Neri E, Miele V, Coppola F, et al. Use of CT and artificial intelligence in suspected or COVID-19 positive patients: statement of the Italian Society of Medical and Interventional Radiology. Radiol Med. 2020. PMID: 32350794. doi:10.1007/s11547-020-01197-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。